PODD logo

Insulet Corporation Stock Price

NasdaqGS:PODD Community·US$22.6b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 18 Fair Values set on narratives written by author

PODD Share Price Performance

US$314.52
81.42 (34.93%)
12.7% undervalued intrinsic discount
US$360.17
Fair Value
US$314.52
81.42 (34.93%)
12.7% undervalued intrinsic discount
US$360.17
Fair Value
Price US$314.52
AnalystConsensusTarget US$360.17

PODD Community Narratives

AnalystConsensusTarget·
Fair Value US$360.17 12.4% undervalued intrinsic discount

Digital Diabetes Care Will Expand International Market Opportunities

0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative

Recent PODD News & Updates

Market Participants Recognise Insulet Corporation's (NASDAQ:PODD) Revenues Pushing Shares 26% Higher

Sep 06
Market Participants Recognise Insulet Corporation's (NASDAQ:PODD) Revenues Pushing Shares 26% Higher

There May Be Reason For Hope In Insulet's (NASDAQ:PODD) Disappointing Earnings

Aug 14
There May Be Reason For Hope In Insulet's (NASDAQ:PODD) Disappointing Earnings

Insulet Corporation Key Details

US$2.4b

Revenue

US$703.7m

Cost of Revenue

US$1.7b

Gross Profit

US$1.4b

Other Expenses

US$236.1m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 06, 2025
Earnings per share (EPS)
3.35
Gross Margin
70.18%
Net Profit Margin
10.01%
Debt/Equity Ratio
95.7%

Insulet Corporation Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

2 Risks
1 Reward

About PODD

Founded
2000
Employees
3900
CEO
Ashley McEvoy
WebsiteView website
www.insulet.com

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

U.S. Market Performance

  • 7 Days: -2.8%
  • 3 Months: 5.3%
  • 1 Year: 13.4%
  • Year to Date: 11.7%
Over the last 7 days, the market has dropped 2.8%, driven by a decline of 2.5% in the Information Technology sector. In contrast to the last week, the market is actually up 13% over the past year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›